Logo image of MEIP

MEI PHARMA INC (MEIP) Stock Fundamental Analysis

NASDAQ:MEIP - Nasdaq - US55279B3015 - Common Stock - Currency: USD

4.79  -0.04 (-0.83%)

After market: 4.92 +0.13 (+2.71%)

Fundamental Rating

4

MEIP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. While MEIP has a great health rating, there are worries on its profitability. MEIP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MEIP had positive earnings in the past year.
In the past year MEIP has reported a negative cash flow from operations.
MEIP had negative earnings in 4 of the past 5 years.
In the past 5 years MEIP reported 4 times negative operating cash flow.
MEIP Yearly Net Income VS EBIT VS OCF VS FCFMEIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -152.38%, MEIP is doing worse than 84.73% of the companies in the same industry.
Looking at the Return On Equity, with a value of -162.03%, MEIP is doing worse than 64.55% of the companies in the same industry.
Industry RankSector Rank
ROA -152.38%
ROE -162.03%
ROIC N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
MEIP Yearly ROA, ROE, ROICMEIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

MEIP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MEIP Yearly Profit, Operating, Gross MarginsMEIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

9

2. Health

2.1 Basic Checks

MEIP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MEIP has been reduced compared to 1 year ago.
The number of shares outstanding for MEIP has been increased compared to 5 years ago.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEIP Yearly Shares OutstandingMEIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
MEIP Yearly Total Debt VS Total AssetsMEIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

MEIP has an Altman-Z score of 40.43. This indicates that MEIP is financially healthy and has little risk of bankruptcy at the moment.
MEIP has a Altman-Z score of 40.43. This is amongst the best in the industry. MEIP outperforms 97.45% of its industry peers.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 40.43
ROIC/WACCN/A
WACC9.77%
MEIP Yearly LT Debt VS Equity VS FCFMEIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 16.78 indicates that MEIP has no problem at all paying its short term obligations.
The Current ratio of MEIP (16.78) is better than 90.36% of its industry peers.
MEIP has a Quick Ratio of 16.78. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 16.78, MEIP belongs to the best of the industry, outperforming 90.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.78
Quick Ratio 16.78
MEIP Yearly Current Assets VS Current LiabilitesMEIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

MEIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 157.67%, which is quite impressive.
MEIP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
Measured over the past years, MEIP shows a very strong growth in Revenue. The Revenue has been growing by 67.72% on average per year.
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MEIP will show a very negative growth in Earnings Per Share. The EPS will decrease by -67.16% on average per year.
Based on estimates for the next years, MEIP will show a very strong growth in Revenue. The Revenue will grow by 85.04% on average per year.
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MEIP Yearly Revenue VS EstimatesMEIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 1B 2B 3B
MEIP Yearly EPS VS EstimatesMEIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1.79 indicates a rather cheap valuation of MEIP.
99.09% of the companies in the same industry are more expensive than MEIP, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MEIP to the average of the S&P500 Index (26.73), we can say MEIP is valued rather cheaply.
MEIP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 1.79
Fwd PE N/A
MEIP Price Earnings VS Forward Price EarningsMEIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEIP Per share dataMEIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as MEIP's earnings are expected to decrease with -37.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%

More info and screens

0

5. Dividend

5.1 Amount

MEIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEI PHARMA INC

NASDAQ:MEIP (8/12/2025, 7:51:16 PM)

After market: 4.92 +0.13 (+2.71%)

4.79

-0.04 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13
Earnings (Next)09-17 2025-09-17/amc
Inst Owners9.02%
Inst Owner Change-0.01%
Ins Owners1.24%
Ins Owner Change0%
Market Cap143.13M
Analysts43.33
Price Target6.12 (27.77%)
Short Float %0.27%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.75
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.79
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.32
P/tB 7.32
EV/EBITDA N/A
EPS(TTM)2.67
EY55.74%
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS0.65
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -152.38%
ROE -162.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.78
Quick Ratio 16.78
Altman-Z 40.43
F-Score2
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)52.51%
Cap/Depr(5y)242.29%
Cap/Sales(3y)0.42%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
EBIT growth 1Y-200.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.82%
OCF growth 3YN/A
OCF growth 5YN/A